Tweaking Taxol points way to a greener, more productive future

As the effective cancer-treatment drug Taxol enters its next generation, Michigan State University announces discoveries which point to both environmentally friendly ways to produce more Taxol, and ultimately innovations to produce a more potent second-generation drug.

Kevin Walker, a chemistry and biochemistry and molecular biology assistant professor, in the March 24 issue of Chemistry & Biology, reports a step toward manufacturing more-potent Taxol molecules that could potentially reduce treatment dosages. The methods described minimize dangerous chemical usage, and put E.coli to work in the production process.

"We're trying to develop a biosynthetic process for the drugs that circumvents the use of organic solvent-based methods requiring costly waste management," Walker said. "This attempt is a green chemistry approach to produce more potent versions of Taxol."

Taxol generically known as paclitaxel is a top-selling cancer-fighting drug. It's most commonly used against ovarian and breast cancers, but currently is used in certain aspects of heart disease treatment, and is showing promise in Alzheimer's therapy.

Taxol is derived in small quantities from the Pacific yew tree. To fulfill large-scale production, pharmaceutical companies isolate, from the tree, an abundant natural product that is synthetically converted to Taxol in the laboratory.

Now, as abundant molecules from the yew are being synthetically modified for new, more potent versions of Taxol, Walker, along with Catherine Loncaric, a visiting research associate, and undergraduate Erin Merriweather, is looking for alternative, biological routes to introduce the modifications. Walker's laboratory makes use of recently identified genes of the yew that produce enzymes that craft the pathway to Taxol. The targets: five enzymes that biosynthetically decorate the core of the Taxol molecule.

The enzymes in natural and, potentially, genetically modified form can


Page: 1 2

Related biology news :

1. Tweaking the treatment for restless legs
2. Protein identified that regulates effectiveness of Taxol chemotherapy in breast cancer
3. Tipping points
4. Study points to new way to predict death risk from torn aorta
5. Genes activity points to more lethal subtype of AML
6. Existence of muscle-building stem cells points to regenerative therapies for muscular disease
7. Newly identified mechanism for silencing genes points to possible anti-cancer strategies
8. Massive gene screening points way to more effective chemotherapy
9. Lizards shout against a noisy background to get points across
10. International study points to new breast cancer-susceptibility gene
11. Imaging pinpoints brain regions that see the future

Post Your Comments:

(Date:8/19/2019)... ... August 19, 2019 , ... Since ... use of ultra-thin two dimensional slices which are placed on microscope slides, stained ... complex tissues and complicated features such as vasculature and thus researchers in the ...
(Date:8/15/2019)... ... ... Deep Science Ventures (DSV), a new paradigm for applied science, today announced ... 100 companies over the next 10 years to address the urgent need for new ... was founded to create a better method for launching science companies; one that takes ...
(Date:8/15/2019)... ... , ... Serialization deadlines in the US and European Union ... becomes fully applied in the United States in 2023, pharmaceutical companies are scrutinizing ... most regulations?including the Drug Supply Chain Security Act (DSCSA)?have required minimal system capabilities. ...
Breaking Biology News(10 mins):
(Date:8/15/2019)... ... August 15, 2019 , ... PathSensors announced today that Roger ... of the Institute of Food Technologists (IFT) Board of Directors, Illinois Institute of ... for Food Safety and Applied Nutrition (JIFSAN) Advisory Council and the University of ...
(Date:8/14/2019)... STATE COLLEGE, Pa. (PRWEB) , ... August 13, ... ... leader in nuclear receptor and in vitro toxicology testing solutions, announced the appointment ... of healthcare industry experience to the Board. , Mark McLoughlin will lend his ...
(Date:8/14/2019)... ... August 13, 2019 , ... ... prepackaged mobile phases for QC laboratories. After gaining a few significant clients, Lifecycle ... approach into a valued supplier of manufacturing processing solutions, including reagents for tissue ...
(Date:8/8/2019)... , ... August 08, 2019 , ... ... Agents for sales and service organizations, today announced that the company’s Studio ... Award for the IVA market . Inference will officially accept the award at ...
Breaking Biology Technology:
Cached News: